Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H6QU
|
||||
| Former ID |
DIB015641
|
||||
| Drug Name |
Apomorphine
|
||||
| Synonyms |
Apomorphine (intranasal, Parkinson's disease)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Approved | [1], [2] | ||
| Company |
Archimedes Pharma Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H17NO2
|
||||
| InChI |
InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
|
||||
| InChIKey |
VMWNQDUVQKEIOC-CYBMUJFWSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7978719, 8153735, 11114270, 11466129, 11467249, 11485757, 14823961, 14848260, 24262970, 26752261, 29225019, 46508653, 47216673, 47365074, 47365075, 47662161, 47662162, 47662163, 48110346, 48184887, 48259117, 48415574, 49658769, 49698343, 49871434, 50322702, 51091791, 57323108, 85788349, 85856298, 92308726, 92729815, 93622853, 103167211, 103916308, 104310845, 124887059, 124887060, 126522630, 129497604, 134337595, 134971357, 135304977, 135649950, 137001467, 142333205, 144204518, 160964058, 163667986, 164788060
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02339064) Infusion of Apomorphine: Long-term Safety Study. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 33). | ||||
| REF 3 | Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse. 2009 May;63(5):378-89. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.